Strengthening reagent portfolio through BioImage
Fisher Biosciences has acquired BioImage to expand its offering in high content screening and analysis reagent technologies
BioImage, which is based in Copenhagen, Denmark, complements Fisher Biosciences' existing Cellomics business.
The Cellomics platform includes automated imaging instrumentation, BioApplication image analysis software, high content informatics software and HitKit HCS reagent kits.
The entire Cellomics product portfolio is fully integrated to improve the quality and productivity of high content cell-based assays.
BioImage is a leader in the field of high content pathway analysis, providing the life-science market with products, services and licenses that are based on its redistribution technology.
Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.
"The addition of BioImage further enhances our portfolio of high content cell-based assays and reagents," said Ron Lowy, president and chief executive officer of Fisher Biosciences.
"Adding BioImage's Redistribution IP, assays, cell-lines and services to our already strong offering of high content screening instrumentation, software, siRNA and assay reagent kits, provides a more complete range of options to customers and strengthens Fisher's leadership position in high content screening." Fisher will continue operations in Copenhagen.
More than 60 customers shared their experiences and provided insight for development of new tools during Cellomics's second annual European user group meeting held recently in Dublin
Cellomics, the creator of high content screening (HCS), has reached an agreement to provide maintenance and service support to HCS customers of Beckman Coulter
Cellomics launches its new VTI Live option for the ArrayScan VTI high-content screening (HCS) reader, offering customers the ability to run automated live-cell kinetic assays
Agreement involves high content screening (HCS) technology and specific HCS assays such as cytoplasm-nuclear translocation, characterisation of cellular toxicity, and receptor internalisation
Collaboration objectives include a mix of applications and new product development, as well as establishing a key demonstration centre for high content screening (HCS) in Europe